154.31
price up icon0.15%   +0.23
 
loading
Agilent Technologies Inc. stock is currently priced at $154.31, with a 24-hour trading volume of 1.30M. It has seen a +0.15% increased in the last 24 hours and a +12.80% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $153.7 pivot point. If it approaches the $154.9 resistance level, significant changes may occur.
Previous Close:
$154.08
Open:
$152.57
24h Volume:
1.30M
Market Cap:
$45.22B
Revenue:
$6.74B
Net Income/Loss:
$1.24B
P/E Ratio:
40.40
EPS:
3.82
Net Cash Flow:
$1.65B
1W Performance:
+6.32%
1M Performance:
+12.80%
6M Performance:
+35.13%
1Y Performance:
+22.19%
1D Range:
Value
$152.57
$154.84
52W Range:
Value
$96.80
$154.84

Agilent Technologies Inc. Stock (A) Company Profile

Name
Name
Agilent Technologies Inc.
Name
Phone
408-345-8886
Name
Address
5301 Stevens Creek Boulevard, Santa Clara, CA
Name
Employee
14,500
Name
Twitter
@agilent
Name
Next Earnings Date
2024-05-29
Name
Latest SEC Filings
Name
A's Discussions on Twitter

Agilent Technologies Inc. Stock (A) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-13-23 Initiated Wolfe Research Outperform
Dec-12-23 Downgrade BofA Securities Buy → Neutral
Nov-17-23 Downgrade UBS Buy → Neutral
Sep-28-23 Initiated Bernstein Mkt Perform
Jul-31-23 Downgrade Evercore ISI Outperform → In-line
May-24-23 Reiterated Barclays Equal Weight
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated Citigroup Neutral
May-24-23 Reiterated Credit Suisse Outperform
May-24-23 Reiterated Evercore ISI Outperform
May-24-23 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
May-24-23 Reiterated Robert W. Baird Outperform
May-24-23 Reiterated SVB Securities Outperform
May-24-23 Reiterated Stifel Hold
May-24-23 Reiterated TD Cowen Outperform
May-24-23 Reiterated Wells Fargo Overweight
May-11-23 Initiated Barclays Equal Weight
Jan-10-23 Upgrade Wells Fargo Equal Weight → Overweight
Aug-25-22 Initiated Credit Suisse Outperform
Jul-20-22 Initiated UBS Buy
Jul-08-22 Downgrade Citigroup Buy → Neutral
Apr-25-22 Downgrade Wells Fargo Overweight → Equal Weight
Feb-23-22 Reiterated BofA Securities Buy
Feb-23-22 Reiterated Citigroup Buy
Feb-23-22 Reiterated Cowen Outperform
Feb-23-22 Reiterated Evercore ISI Outperform
Feb-23-22 Reiterated Stifel Hold
Feb-23-22 Reiterated Wells Fargo Overweight
Nov-23-21 Reiterated BofA Securities Buy
Nov-23-21 Reiterated Cowen Outperform
Nov-23-21 Reiterated Stifel Hold
Mar-18-21 Upgrade Citigroup Neutral → Buy
Feb-17-21 Upgrade BofA Securities Neutral → Buy
Dec-02-20 Initiated Goldman Buy
Nov-25-20 Upgrade UBS Neutral → Buy
Nov-17-20 Upgrade Cleveland Research Neutral → Buy
Nov-10-20 Initiated KeyBanc Capital Markets Overweight
Sep-30-20 Initiated Atlantic Equities Neutral
Aug-19-20 Reiterated BofA Securities Neutral
Aug-19-20 Reiterated Citigroup Neutral
Aug-19-20 Reiterated Jefferies Buy
Aug-19-20 Reiterated Robert W. Baird Outperform
Aug-19-20 Reiterated SVB Leerink Outperform
Aug-19-20 Reiterated Stifel Hold
Aug-19-20 Reiterated Wells Fargo Overweight
Feb-24-20 Downgrade Needham Buy → Hold
Jan-08-20 Initiated Wells Fargo Overweight
Jan-07-20 Initiated Citigroup Neutral
Nov-26-19 Reiterated Needham Buy
Nov-15-19 Initiated Stifel Hold
Oct-18-19 Downgrade UBS Buy → Neutral
Jul-16-19 Downgrade BofA/Merrill Buy → Neutral
Jul-15-19 Downgrade Barclays Overweight → Equal Weight
View All

Agilent Technologies Inc. Stock (A) Financials Data

Agilent Technologies Inc. (A) Revenue 2024

A reported a revenue (TTM) of $6.74 billion for the quarter ending January 31, 2024, a -2.81% decline year-over-year.
loading

Agilent Technologies Inc. (A) Net Income 2024

A net income (TTM) was $1.24 billion for the quarter ending January 31, 2024, a -6.58% decrease year-over-year.
loading

Agilent Technologies Inc. (A) Cash Flow 2024

A recorded a free cash flow (TTM) of $1.65 billion for the quarter ending January 31, 2024, a +55.42% increase year-over-year.
loading

Agilent Technologies Inc. (A) Earnings per Share 2024

A earnings per share (TTM) was $4.20 for the quarter ending January 31, 2024, a -5.19% decline year-over-year.
loading

Agilent Technologies Inc. Stock (A) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Binns Philip
Senior Vice President
Mar 25 '24
Sale
147.54
2,827
417,096
9,997
McMullen Michael R.
CEO and President
Mar 08 '24
Sale
150.00
52,297
7,844,550
253,909
Gonsalves Rodney
V.P., Corporate Controller
Mar 07 '24
Sale
149.00
4,828
719,348
21,329
FIELDS HEIDI
Director
Mar 05 '24
Sale
144.34
1,658
239,316
54,976
Binns Philip
Senior Vice President
Dec 27 '23
Sale
139.78
2,880
402,566
12,824
Gonsalves Rodney
V.P., Corporate Controller
Dec 18 '23
Sale
137.69
1,500
206,538
26,133
Ancher-Jensen Henrik
Sr Vice President
Dec 15 '23
Option Exercise
111.36
11,703
1,303,235
108,835
Ancher-Jensen Henrik
Sr Vice President
Dec 15 '23
Sale
138.36
26,331
3,643,157
82,504
McMullen Michael R.
CEO and President
Dec 13 '23
Option Exercise
42.12
2,751
115,872
308,957
McMullen Michael R.
CEO and President
Dec 13 '23
Sale
130.00
2,751
357,630
306,206
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment services; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients. The Agilent CrossLab segment offers GC and LC columns, sample preparation products, custom chemistries, and various laboratory instrument supplies; and startup, operational, training, and compliance support, as well as asset management and consultation services. The company markets its products through direct sales, electronic commerce, resellers, manufacturers' representatives, and distributors. It has collaboration with the University of Southern California Michelson Center for Convergent Bioscience. Agilent Technologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.
$540.94
price down icon 1.38%
diagnostics_research IQV
$235.00
price up icon 0.56%
diagnostics_research MTD
$1,530.55
price up icon 0.70%
$315.83
price down icon 1.86%
diagnostics_research WAT
$360.51
price down icon 0.35%
Cap:     |  Volume (24h):